Chemotherapy for small cell lung cancer

Seminars in Oncology

Volumn 30, Issue 1, 2003, Pages 9-25

  Sandler, Alan B ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROCARBAZINE; TENIPOSIDE; TOPOTECAN; VINCRISTINE;

ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; HUMAN; LUNG SMALL CELL CANCER; MYALGIA; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SKULL IRRADIATION; STEM CELL TRANSPLANTATION; STOMATITIS;

EID: 0037328208     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50012     Document Type: Review

References (81)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics 2002. CA Cancer J Clin 52:23-47, 2002
2. Kristjansen PEG, Hansen HH: Management of small cell lung cancer: A summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J Natl Cancer Inst 82:263-266, 1990
3. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
4. Blackstein ME: Advances in chemotherapy for small cell lung cancer. Semin Oncol 21:38-42, 1994 (suppl 11)
5. Maurer LH, Tulloh M, Weiss R, et al: A randomized combined modality trial in small cell carcinoma of the lung. Cancer 45:30-39, 1980
6. Woods RL, Levi JA, et al: Chemotherapy for small cell lung cancer (SCLC): A randomised study of maintenance therapy with cyclophosphamide, adriamycin and vincristine (CAV) after remission induction with cis-platinum (CIS DDP), VP16-213 and radiotherapy. Proc Am Soc Clin Oncol 3:214, 1984 (abstr)
7. Cullen M, Morgan D, Gregory W, et al: Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial. Cancer Chemother Pharmacol 17:157-160, 1986
8. Byrne MJ, Van Hazel G, Trotter J, et al: Maintenance chemotherapy in limited small cell lung cancer: A randomised controlled clinical trial. Br J Cancer 60:413-418, 1989
9. Bleehen NM, Fayers PM, Girling DJ, et al: Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 59:584-590, 1989
10. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230-240, 1990
11. Lebeau B, Chastang CL, Allard P, et al: Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: Definitive results of a randomized clinical trial. Eur Respir J 5:286-290, 1992
12. Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. J Clin Oncol 11:1230-1240, 1993
13. Jarry O, Fournel P, et al: A randomised trial of 4 versus 8 courses of chemotherapy with ifosfamide epirubicin and etoposide (EVI) in extensive small cell lung cancer (SCLC). International Association for the Study of Lung Cancer-Small Cell Lung Cancer, Denver, CO, 1994 (abstr)
14. Beith JM, Clarke SJ, Woods RL, et al: Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 32A:438-443, 1996
15. Sculier JP, Paesmans M, Bureau G, et al: Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol 14:2337-2344, 1996
16. Spiro SG, Souhami RL, Geddes DM, et al: Duration of chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. Br J Cancer 59:578-583, 1989
17. Johnson DH, Kim K, Sause W, et al: Cisplatin (p) & etoposide (e) + thoracic radiotherapy (TRT) administered once or twice daily (bid) in limited stage (LS) small cell lung cancer (sclc): Final report of intergroup trial 0096. Proc Am Soc Clin Oncol 15:374, 1996 (abstr)
18. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44:3643-3653, 1984
19. Loehrer PJ, Einhorn LH, Greco FA: Cisplatin plus etoposide in small cell lung cancer. Semin Oncol 15:2-8, 1988
20. Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 6:451-456, 1988
21. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451-458, 1987
22. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
23. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
24. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991
25. Furuse K, Fukuoka M, Nishiwaki Y, et al: Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 16:2126-2132, 1998
26. Murray N, Livingston RB, Shephers FA, et al: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17:2300-2308, 1999
27. Cohen MH, Creaven PJ, Fossieck BE, et al: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349-354, 1977
28. Dinwoodie WR, Lyman GH, Williams CC, et al: Intensive combination chemotherapy and radiotherapy for small cell bronchogenic carcinoma (SCBC). Proc Am Assoc Cancer Res 22:505, 1981 (abstr)
29. Mehta C, Vogl SE, Farber S, et al: High-dose cyclophosphamide (c) in the induction (ind) chemotherapy (ct) of small cell lung cancer (sclc) - Minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res 23:165, 1982 (abstr)
30. Figueredo AT, Hryniuk WM, Strautmanis I, et al: Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3:54-64, 1985
31. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
32. Arriagada R, Le Chevalier T, Pierre Pignon J, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 25:1848-1852, 1993
33. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
34. Steward WP, von Pawel J, Gatzemeier U, et al: Effects of granulocyte colony-stimulating factor and dose-intensification of V̇-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 16:642-650, 1998
35. Thatcher N, Girling DJ, Hopwood P, et al: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 18:395-404, 2000
36. Bunn PA Jr, Crowley J, Kelly K, et al: Chemoradiotherapy with/without granulocyte-macrophage colony-stimulating factor in the treatment of limited stage small cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13:1632-1641, 1995
37. Sculier JP, Paesmans M, Lecomte J, et al: A three arm phase III randomized trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 85:1444-1451, 2001
38. Antman KH, Souhami RL, et al: High-dose chemotherapy in solid tumors. A review of published data in selected tumors and commentary. Ann Oncol 4:29-44, 1993 (suppl 1)
39. Humblet Y, Symann M, Bosly A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 5:1864-1873, 1987
40. Elias A, Ayash L III, Frei E, et al: Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 85:559-566, 1993
41. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of scheduling of on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333-1340, 1989
42. Clark PI, Cottier B: The activity of 10-, 14-, and 21-day schedules of single agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 19:36-39, 1992 (suppl 14)
43. Smit EF, Postmus PE: A phase II study of oral etoposide 100 mg/day for 21 days every 4 weeks in untreated elderly and poor performance status small cell lung cancer patients. Cancer Treat Res 7:136, 1991 (abstr)
44. Doward AJ: A prospective study of low dose oral etoposide in poor prognosis small cell lung cancer. Cancer Treat Res 7:111, 1991 (abstr)
45. Medical Research Council Lung Cancer Working Party: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Lancet 348:563-566, 1996
46. Harper P, Underhill C, Ruiz de Elvira MC, et al: A randomized study of oral etoposide versus combination chemotherapy in poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol 15:27, 1996 (abstr)
47. Negoro S, Fukuoka M, Niitani H, et al: Phase II study of cpt-11, new camptothecin derivative, in small cell lung cancer (sclc). Proc Am Soc Clin Oncol 10:241, 1991 (abstr)
48. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
49. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A:1058- 1060, 1994
50. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (sclc). National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 75:283-285, 1994
51. Ettinger D, Findelstein D, Ritch P, et al: Randomized trial of single agents vs combination chemotherapy in extensive stage small cell lung cancer (sclc). Proc Am Soc Clin Oncol 11:295, 1992 (abstr)
52. Ettinger D, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
53. Kirschling RJ, Jung SH, Jett JR, et al: A phase II trial of Taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (scc). Proc Am Soc Clin Oncol 13:326, 1994 (abstr)
54. Wanders J, Ardizzoni A, Hansen HH, et al: Phase II study of topotecan in refractory and sensitive small cell lung cancer (sclc). Proc Am Assoc Cancer Res 36:237, 1995 (abstr)
55. Schiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
56. Jassem J, Kamicka-Mlodkowska H, Van Pottelsberghe CH, et al: Phase II study of vinorelbine (navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A:1720-1722, 1993
57. Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 53:169-172, 1996
58. Evans WK, Stewart DJ, Shepherd FA, et al: VP-16, ifosfamide, and cisplatin (VIP) for extensive small cell lung cancer. Eur J Cancer 30A:299-303, 1994
59. Loehrer PJ, Rynard S, Ansari R, et al: Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer 69:669-673, 1992
60. Munoz MA, Arrivi A, Guaraz R, et al: VP-16, ifosfamide, and cisplatin (VIP) as treatment of small cell lung cancer: A preliminary report. Presented at Fourth European Conference on Clinical Oncology and Cancer Nursing, Madrid, Spain, Federation of European Cancer Societies, 1987, p 26
61. Loehrer PJ, Ansary R, Gonin R, et al: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol 13:2594-2599, 1995
62. Miyomoto H, Nakabayashi T, Isobe H, et al: A phase III trial of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 49:431-435, 1992
63. Bunn PA Jr, Kelly K: New treatment agents for advanced small cell and non-small cell lung cancer. Semin Oncol 22:53-63, 1995 (suppl 6)
64. Glisson BS, Kurie JM, Perez-Soler R, et al: Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17:2309-2315, 1999
65. Kelly K, Lovato L, Bunn PA Jr, et al: Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. Clin Cancer Res 7:2325-2329, 2001
66. Mavroudis D, Papadakis E, Veslemes M, et al: A multicenter randomized phase II study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as frontline treatment in patients with small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 19:484a, 2000 (abstr)
67. Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 21:293a, 2002 (abstr)
68. Hainsworth JD, Burris HA III, Greco FA: Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: A review of the Sarah Cannon Cancer Center experience. Semin Oncol 28:43-47, 2001 (suppl 4)
69. Thomas P, Castelnau O, Paillotin D, et al: Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A Group Francais de Pneumo-Cancerologie study. J Clin Oncol 19:1320-1325, 2001
70. Jett JR, Day R, Levitt M, et al: Topotecan and paclitaxel in extensive stage small cell lung cancer patients without prior therapy. Lung Cancer 18:13, 1997 (suppl 1; abstr 28)
71. Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001
72. Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993
73. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75, 1995
74. Pei XH, Nakanishi Y, Takayama K, et al: Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 8:231-237, 1997
75. Kudoh S, Fujiwara Y, Takada Y, et al: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16:1068-1074, 1998
76. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
77. Turrissi AT, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
78. Levitan N, Dowlati A, Shina D, et al: Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 18:1102-1109, 2000
79. Bremnes RM, Sundstrom S, Vilsik J, et al: Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 19:3532-3538, 2001
80. Ettinger DS, Seiferhels WF, Abrams RA, et al: Cisplatin, etoposide, paclitaxel, and concurrent hyperfractionated thoracic radiotherapy for patients with limited disease small cell lung cancer: Preliminary results of RTOG 96009. Proc Am Soc Clin Oncol 19:490a, 2000 (abstr)
81. Sandler A, Declerck L, Wagner H, et al: A phase II study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 19:491a, 2000 (abstr)